腫瘤細胞的代謝重編程是癌癥發(fā)生和發(fā)展的重要特征。通過調控代謝途徑，腫瘤細胞能夠滿足快速增殖的需求，其中糖酵解和磷酸戊糖途徑（PPP）是2條關鍵的代謝途徑。近期研究發(fā)現(xiàn)，糖酵解與PPP之間存在復雜的代謝串擾，腫瘤細胞通過調節(jié)兩條途徑的交叉點，如葡萄糖-6-磷酸（G6P）和果糖-6-磷酸（F6P），靈活調整代謝通量以適應腫瘤微環(huán)境的變化。這些代謝交叉點不僅揭示了腫瘤細胞代謝的復雜性，也為靶向藥物的開發(fā)提供了新的方向。當前，針對這些代謝交叉點的靶向藥物研究取得了積極進展，抑制葡萄糖-6-磷酸脫氫酶（G6PD）和轉酮醇酶（TKT）的藥物已顯示出良好的抗腫瘤效果。此外，一些中藥活性成分也顯示出可調節(jié)糖酵解和PPP來增強化療藥物的療效，這為聯(lián)合用藥提供了新的思路。因此，深入探索糖酵解與PPP之間的串擾機制及其在癌癥治療中的應用，將為靶向藥物的開發(fā)和現(xiàn)有治療策略的優(yōu)化提供重要的理論依據(jù)和實踐指導。重點討論這些代謝交叉點的生物學意義，以及靶向這些代謝途徑交叉點的藥物開發(fā)現(xiàn)狀，探討其在癌癥治療中的潛力與挑戰(zhàn)。

Metabolic reprogramming of tumor cells is an important feature of cancer development and progression. By regulating metabolic pathways, tumor cells are able to meet the demands of rapid proliferation, of which glycolysis and the pentose phosphate pathway (PPP) are two key metabolic pathways. Recent studies have revealed a complex metabolic crosstalk between glycolysis and PPP. Tumor cells flexibly adjust their metabolic fluxes to adapt to the changes in the tumor microenvironment by regulating the intersection of the two pathways, such as glucose-6-phosphate (G6P) and fructose-6-phosphate (F6P). These metabolic crossroads not only reveal the complexity of tumor cell metabolism, but also provide new directions for targeted drug development. Currently, the research on targeted drugs against these metabolic crossroads has made positive progress, and drugs inhibiting G6P dehydrogenase (G6PD) and transketolase (TKT) have shown good anti-tumor effects. In addition, some active ingredients of traditional Chinese medicine have been shown to modulate glycolysis and PPP to enhance the efficacy of chemotherapeutic drugs, which provides a new idea for the combination of drugs. Therefore, in-depth exploration of the crosstalk mechanism between glycolysis and PPP and its application in cancer therapy will provide an important theoretical basis and practical guidance for the development of targeted drugs and the optimization of existing therapeutic strategies. In this paper, we will focus on the biological significance of these metabolic crossovers and the current status of drug development targeting these metabolic pathway crossovers to explore their potential and challenges in cancer therapy

R979.1

天津市自然科學基金項目（23JCZXJC00150、23JCJQJC00040）